KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma

被引：0
|
作者：
Atkins, Michael B.
Carlino, Matteo S.
Hill, Andrew G.
McNeil, Catriona M.
Long, Georgina V.
Atkinson, Victoria
Cebon, Jonathan S.
Jameson, Michael B.
Hwu, Wen-Jen
Thompson, John A.
Anderson, James
Moreno, Blanca Homet
Ibrahim, Nageatte
Ribas, Antoni
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT065
引用
收藏
页数：2
相关论文
共 50 条
  • [1] KEYNOTE 029: Phase 1/2 randomized study of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma
    Atkins, M. B.
    Carlino, M. S.
    Hill, A. G.
    McNeil, C. M.
    Ribas, A.
    Atkinson, V.
    Cebon, J. S.
    Jameson, M. B.
    Hwu, W-J.
    Thompson, J. A.
    Anderson, J.
    Moreno, B. Homet
    Ibrahim, N.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.
    Carlino, Matteo S.
    Atkinson, Victoria
    Cebon, Jonathan S.
    Jameson, Michael B.
    Fitzharris, Bernie M.
    McNeil, Catriona M.
    Hill, Andrew G.
    Ribas, Antoni
    Atkins, Michael B.
    Thompson, John A.
    Hwu, Wen-Jen
    Hodi, F. Stephen
    Menzies, Alexander M.
    Guminski, Alexander David
    Kefford, Richard
    Shu, Xinxin
    Ibrahim, Nageatte
    Moreno, Blanca Hornet
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.
    Long, Georgina V.
    Atkinson, Victoria
    Cebon, Jonathan S.
    Jameson, Michael B.
    Fitzharris, Bernie M.
    McNeil, Catriona M.
    Hill, Andrew Graham
    Ribas, Antoni
    Atkins, Michael B.
    Thompson, John A.
    Hwu, Wen-Jen
    Hodi, F. Stephen
    Menzies, Alexander M.
    Guminski, Alexander David
    Kefford, Richard
    Shu, Xinxin
    Ebbinghaus, Scot
    Ibrahim, Nageatte
    Carlino, Matteo S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Standard-dose pembrolizumab (pembro) plus alternate-dose ipilimumab (ipi) in advanced melanoma: Initial analysis of KEYNOTE-029 cohort 1C.
    Long, Georgina V.
    Robert, Caroline
    Butler, Marcus O.
    Couture, Felix
    Carlino, Matteo S.
    O'Day, Steven
    Atkinson, Victoria
    Cebon, Jonathan S.
    Brown, Michael Paul
    Dalle, Stephane
    Hill, Andrew Graham
    Gibney, Geoffrey Thomas
    McCune, Steven L.
    Menzies, Alexander M.
    Niu, Cuizhen
    Ibrahim, Nageatte
    Moreno, Blanca Homet
    Diab, Adi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.
    Choueiri, Toni K.
    Hodi, F. Stephen
    Thompson, John A.
    McDermott, David F.
    Hwu, Wen-Jen
    Lawrence, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] PEMBROLIZUMAB PLUS IPILIMUMAB FOR ADVANCED MELANOMA: RESULTS OF THE KEYNOTE-029 EXPANSION COHORT
    Long, G.
    Atkinson, V.
    Cebon, J. S.
    Jameson, M. B.
    Fitzharris, B. M.
    McNeil, C. M.
    Hill, A. G.
    Ribas, A.
    Atkins, M. B.
    Thompson, J. A.
    Hwu, W-J
    Hodi, F. S.
    Menzies, A. M.
    Guminski, A. D.
    Kefford, R.
    Shu, X.
    Ebbinghaus, S.
    Ibrahim, N.
    Carlino, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 60 - 61
  • [7] Randomized phase II trial (PORTSIDE) evaluating encorafenib (enco) and binimetinib (bini) plus pembrolizumab (pembro) versus nivolumab (nivo) and ipilimumab (ipi) for the treatment of advanced BRAF-mutant melanoma
    Schadendorf, D.
    Dummer, R.
    Ribas, A.
    Robert, C.
    Sullivan, R. J.
    King, A.
    Polli, A.
    di Pietro, A.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S700 - S700
  • [8] Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
    Long, Georgina, V
    Robert, Caroline
    Butler, Marcus O.
    Couture, Felix
    Carlino, Matteo S.
    O'Day, Steven
    Atkinson, Victoria
    Cebon, Jonathan S.
    Brown, Michael P.
    Dalle, Stephane
    Hill, Andrew G.
    Gibney, Geoffrey T.
    McCune, Steven
    Menzies, Alexander M.
    Niu, Cuizhen
    Ibrahim, Nageatte
    Moreno, Blanca Homet
    Diab, Adi
    CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5280 - 5288
  • [9] Phase I/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H.
    Gubens, Matthew A.
    Sequist, Lecia V.
    Stevenson, James
    Powell, Steven Francis
    Villaruz, Liza Cosca
    Gadgeel, Shirish M.
    Langer, Corey J.
    Patnaik, Amita
    Borghaei, Hossein
    Jalal, Shadia Ibrahim
    Fiore, Joseph
    Ge, Joy Yang
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] PATIENT-REPORTED UTILITY ON PEMBROLIZUMAB (PEMBRO) AND IPILIMUMAB (IPI) AMONG IPI NAIVE PATIENTS WITH ADVANCED MELANOMA
    Stevinson, K.
    Zhou, W.
    Hille, D.
    Wang, J.
    VALUE IN HEALTH, 2016, 19 (03) : A157 - A158
12345